Small-animal PET imaging of amyloid-beta plaques with [ 11c]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Manook, André ^a   Yousefi, Behrooz H ^a   Willuweit, Antje ^b,e   Platzer, Stefan ^a,f   Reder, Sybille ^a   Voss, Andreas ^c   Huisman, Marc ^a,g   Settles, Markus ^a   Neff, Frauke ^a,h   Velden, Joachim ^b,c   Schoor, Michael ^d   von der Kammer, Heinz ^b   Wester, Hans Jürgen ^a,i   Schwaiger, Markus ^a   Henriksen, Gjermund ^a,j   Drzezga, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b EVOTEC AG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TaconicArtemis GmbH   (Germany)

^e ABX Advanced Biochemical Compounds GmbH   (Germany)

^f Institut fü r Neurowissenschaften und Medizin   (Germany)

^g VU University Medical Center ^*

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PITTSBURGH COMPOUND B; BENZOTHIAZOLE DERIVATIVE; DIAGNOSTIC AGENT; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANATOMIC LANDMARK; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN RADIOGRAPHY; BRAIN REGION; CEREBELLUM CORTEX; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RADIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLUORESCENCE MICROSCOPY; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NEUROIMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOASSAY; RADIOISOTOPE DISTRIBUTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; AGE; ANIMAL; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; TRANSLATIONAL RESEARCH; ULTRASTRUCTURE; VALIDATION STUDY;

ANIMALIA; MUS; MUS MUSCULUS;

AGE FACTORS; ALZHEIMER DISEASE; ANIMALS; BENZOTHIAZOLES; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; MICE, MUTANT STRAINS; MICROSCOPY, FLUORESCENCE; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84857959777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031310     Document Type: Article

References (77)

1. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
2. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.
3. Khachaturian ZS, (2011) Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 253-256.
4. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, et al. (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262.
5. Citron M, (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5: 677-685.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269.
7. Nordberg A, Rinne JO, Kadir A, Langstrom B, (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6: 78-87.
8. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
9. Henriksen G, Hauser AI, Westwell AD, Yousefi BH, Schwaiger M, et al. (2007) Metabolically stabilized benzothiazoles for imaging of amyloid plaques. J Med Chem 50: 1087-1089.
10. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, et al. (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48: 553-561.
11. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, et al. (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50: 1887-1894.
12. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, et al. (2009) Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50: 818-822.
13. Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D, (2010) 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem 53: 933-941.
14. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, et al. (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50: 1251-1259.
15. O'Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, et al. (2009) Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50: 309-315.
16. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, et al. (2009) Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem 109: 623-630.
17. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, et al. (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 51: 913-920.
18. Yousefi BH, Manook A, Drzezga A, von Reutern B, Schwaiger M, et al. (2011) Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging beta-amyloid plaques in Alzheimer's disease. J Med Chem 54: 949-956.
19. Yousefi BH, Drzezga A, von Reutern B, Manook A, Schwaiger M, et al. (2011) A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of beta-Amyloid Plaques. Acs Medicinal Chemistry Letters 2: 673-677.
20. Chatziioannou AF, (2002) PET scanners dedicated to molecular imaging of small animal models. Mol Imaging Biol 4: 47-63.
21. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF, (2009) Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50: 401-408.
22. de Kemp RA, Epstein FH, Catana C, Tsui BM, Ritman EL, (2010) Small-animal molecular imaging methods. J Nucl Med 51 (Suppl 1): 18S-32S.
23. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527.
24. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
25. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, et al. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-945.
26. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100.
27. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292.
28. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, et al. (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6: 231-244.
29. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
30. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, et al. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940-946.
31. Willuweit A, Velden J, Godemann R, Manook A, Jetzek F, et al. (2009) Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS ONE 4: e7931.
32. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J, (2011) Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol.
33. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606.
34. Strome EM, Doudet DJ, (2007) Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol 9: 186-195.
35. Wengenack TM, Reyes DA, Curran GL, Borowski BJ, Lin J, et al. (2011) Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage 54: 113-122.
36. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, et al. (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100: 12462-12467.
37. Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, et al. (2005) In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23: 577-583.
38. Toyama H, Ye D, Ichise M, Liow JS, Cai L, et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32: 593-600.
39. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, et al. (2009) Limitations of Small Animal PET Imaging with [(18)F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimer's Disease. Mol Imaging Biol.
40. Carpenter AP Jr, Pontecorvo MJ, Hefti FF, Skovronsky DM, (2009) The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. Q J Nucl Med Mol Imaging 53: 387-393.
41. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, et al. (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27: 10957-10968.
42. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, et al. (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46: 1959-1972.
43. Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, et al. (2008) Simplified parametric methods for [11C]PIB studies. Neuroimage 42: 76-86.
44. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, et al. (2011) Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B. J Nucl Med 52: 393-400.
45. Ichise M, Liow JS, Lu JQ, Takano A, Model K, et al. (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23: 1096-1112.
46. Dhenain M, El Tannir El Tayara N, Wu TD, Guegan M, Volk A, et al. (2009) Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol Aging 30: 41-53.
47. Poduslo JF, Hultman KL, Curran GL, Preboske GM, Chamberlain R, et al. (2011) Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid beta Protein Antibody-Coated Nanoparticles. J Neuropathol Exp Neurol 70: 653-661.
48. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, et al. (2007) PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis. Brain.
49. Innis RB, (2010) In vivo PET imaging understood from the perspective of in vitro receptor binding. In: Dittrich S, van den Hoff J, Maguire RP, editors. PET Pharmacokinetic Course Manual 2010 Loch Lomond, Scotland pp. 55-67.
50. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, et al. (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23: 2086-2092.
51. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, et al. (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754.
52. Klotz IM, (1982) Numbers of receptor sites from Scatchard graphs: facts and fantasies. Science 217: 1247-1249.
53. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292.
54. Ye L, Morgenstern JL, Lamb JR, Lockhart A, (2006) Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem Biophys Res Commun 347: 669-677.
55. Pfluger T, Vollmar C, Wismuller A, Dresel S, Berger F, et al. (2000) Quantitative comparison of automatic and interactive methods for MRI-SPECT image registration of the brain based on 3-dimensional calculation of error. J Nucl Med 41: 1823-1829.
56. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, et al. (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7: 609-618.
57. Ashe KH, Zahs KR, (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645.
58. Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, et al. (2004) Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging 31: 1136-1145.
59. Zhang W, Oya S, Kung MP, Hou C, Maier DL, et al. (2005) F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 48: 5980-5988.
60. Hefendehl JK, Wegenast-Braun BM, Liebig C, Eicke D, Milford D, et al. (2011) Long-term in vivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J Neurosci 31: 624-629.
61. Schöll M, Almkvist O, Graff C, Nordberg A, (2011) Amyloid imaging in members of a family harbouring the Arctic APP mutation. Alzheimer's & dementia: the journal of the Alzheimer's Association 7: S303.
62. Mustafiz T, Portelius E, Gustavsson MK, Holtta M, Zetterberg H, et al. (2011) Characterization of the Brain beta-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice. Neurodegener Dis.
63. Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, et al. (2008) Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 65: 499-505.
64. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF, (2000) Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101: 939-944.
65. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, et al. (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463.
66. Kemp BJ, Hruska CB, McFarland AR, Lenox MW, Lowe VJ, (2009) NEMA NU 2-2007 performance measurements of the Siemens Inveon preclinical small animal PET system. Phys Med Biol 54: 2359-2376.
67. Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, et al. (2009) Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med 50: 139-147.
68. Franklin KBJ, Paxinos G, (2007) The Mouse Brain in Stereotaxic Coordinates Oxford Academic Press.
69. Schiffer WK, Mirrione MM, Biegon A, Alexoff DL, Patel V, et al. (2006) Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods 155: 272-284.
70. Jones AR, Overly CC, Sunkin SM, (2009) The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci 10: 821-828.
71. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L, (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18: 941-950.
72. Sedgewick G, (2008) Scientific Imaging with Photoshop: Methods, Measurement, and Output Berkeley, CA, USA New Riders.
73. Abcam, (2010) Double immunofluorescence: simultaneous protocol. Protocols and troubleshooting tips Cambridge, UK Procedure for immunofluoresent double staining incubating the antibodies together.
74. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, et al. (2005) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280: 7677-7684.
75. Bruns RF, Lawson-Wendling K, Pugsley TA, (1983) A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal Biochem 132: 74-81.
76. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
77. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ, (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15: 217-227.